Literature DB >> 29872024

Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36.

Yudi Zhu1, Shaosi Liang, Huafeng Pan, Zhongliang Cheng, Xin Rui.   

Abstract

Recently, microRNA-1247 (miR-1247) has been reported to function as tumour suppressor in several cancer types, including pancreatic cancer, hepatocellular cancer and lung cancer. However, the biological function of miR-1247 in bladder cancer and the underlying mechanisms have remained largely uncovered. In this study, the expression of miR-1247 was significantly downregulated, while RAB36 protein was remarkably upregulated in bladder cancer tissues and cell lines compared with that in paired adjacent normal tissues or normal cell line (SU-HUC-1). The function of miR-1247 and RAB36 in the cell viability, proliferation and invasion of bladder cancer cells (T24 and J82) was assessed by CCK-8, colony formation and Transwell assay, respectively. Gain of function studies showed that upregulation of miR-1247 significantly inhibited cell proliferation and invasion capacity of bladder cancer cells. Consistently, downregulation of RAB36 mimicked the suppressive effects of miR-1247 overexpression in bladder cancer cells. Importantly, miR-1247 was confirmed to target the 30untranslated region (UTR) of RAB36 and downregulated its expression using luciferase reporter assay and Western blot assays. In conclusion, these results provide the first clues regarding the role of miR-1247 might be a potential therapeutic agent and diagnostic marker of bladder cancer by inhibiting RAB36 expression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29872024

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  37 in total

Review 1.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A.

Authors:  Cui Chang; Te Liu; Yongyi Huang; Wenxing Qin; Hongtu Yang; Juan Chen
Journal:  Gene       Date:  2016-12-31       Impact factor: 3.688

4.  Rab36 regulates the spatial distribution of late endosomes and lysosomes through a similar mechanism to Rab34.

Authors:  Li Chen; Jingjie Hu; Ye Yun; Tuanlao Wang
Journal:  Mol Membr Biol       Date:  2010-01       Impact factor: 2.857

5.  miR-1247 functions by targeting cartilage transcription factor SOX9.

Authors:  Aida Martinez-Sanchez; Chris L Murphy
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

Review 6.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

7.  MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met.

Authors:  Xin Xu; Hong Chen; Yiwei Lin; Zhenghui Hu; Yeqing Mao; Jian Wu; Xianglai Xu; Yi Zhu; Shiqi Li; Xiangyi Zheng; Liping Xie
Journal:  Mol Cells       Date:  2013-05-30       Impact factor: 5.034

8.  Aberrant expression of RAB1A in human tongue cancer.

Authors:  K Shimada; K Uzawa; M Kato; Y Endo; M Shiiba; H Bukawa; H Yokoe; N Seki; H Tanzawa
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

9.  MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1.

Authors:  Xianglai Xu; Shiqi Li; Yiwei Lin; Hong Chen; Zhenghui Hu; Yeqing Mao; Xin Xu; Jian Wu; Yi Zhu; Xiangyi Zheng; Jindan Luo; Liping Xie
Journal:  J Transl Med       Date:  2013-11-02       Impact factor: 5.531

10.  Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.

Authors:  Ross M Drayton; Ewa Dudziec; Stefan Peter; Simone Bertz; Arndt Hartmann; Helen E Bryant; James Wf Catto
Journal:  Clin Cancer Res       Date:  2014-02-10       Impact factor: 12.531

View more
  6 in total

1.  Decoding pathogenesis factors involved in the progression of ATLL or HAM/TSP after infection by HTLV-1 through a systems virology study.

Authors:  Mohadeseh Zarei Ghobadi; Rahman Emamzadeh; Majid Teymoori-Rad; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2021-08-26       Impact factor: 4.099

2.  A potential prognostic model based on miRNA expression profile in The Cancer Genome Atlas for bladder cancer patients.

Authors:  Yan Liu; Dong Yan Zhu; Hong Jian Xing; Yi Hou; Yan Sun
Journal:  J Biol Res (Thessalon)       Date:  2020-05-19       Impact factor: 1.889

3.  MiR-411 suppresses the development of bladder cancer by regulating ZnT1.

Authors:  Yang Liu; Tao Liu; Hongwei Jin; Lei Yin; Hongyuan Yu; Jianbin Bi
Journal:  Onco Targets Ther       Date:  2018-12-04       Impact factor: 4.147

4.  miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance.

Authors:  Jiansheng Lin; Xinyang Zheng; Xikun Tian; Jun Guan; Haizhan Shi
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

5.  Two circPPFIA1s negatively regulate liver metastasis of colon cancer via miR-155-5p/CDX1 and HuR/RAB36.

Authors:  Haein Ji; Tae Won Kim; Woo Joo Lee; Seong Dong Jeong; Yong Beom Cho; Hyeon Ho Kim
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444

6.  Bioinformatics analysis of long non-coding RNAs involved in nerve regeneration following sciatic nerve injury.

Authors:  Yuanyuan Jia; Ming Zhang; Pei Li; Wenbo Tang; Yao Liu; Yiwen Hu; Qingjun Cui; Ming Liu; Jingjing Jiang
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.